Jean Charles Nault

List of Publications by Year
in descending order

99 papers	10,395 citations	61945 43 h-index	36008 97 g-index
103 all docs	103 docs citations	103 times ranked	12314 citing authors

#	Article	IF	Citations
1	Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma. Gut, 2022, 71, 616-626.	6.1	106
2	Percutaneous radiofrequency ablation for hepatocellular carcinoma developed on nonâ€alcoholic fatty liver disease. Liver International, 2022, 42, 905-917.	1.9	8
3	Preneoplastic lesions in the liver: Molecular insights and relevance for clinical practice. Liver International, 2022, 42, 492-506.	1.9	20
4	Portal hypertension and hepatocellular carcinoma: Navigating uncharted waters. United European Gastroenterology Journal, 2022, 10, 8-9.	1.6	3
5	Performance of non-invasive biomarkers compared with invasive methods for risk prediction of posthepatectomy liver failure in hepatocellular carcinoma. British Journal of Surgery, 2022, 109, 455-463.	0.1	7
6	Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study. Lancet Oncology, The, 2022, 23, 161-171.	5.1	36
7	Structure, Dynamics, and Impact of Replication Stressâ€“Induced Structural Variants in Hepatocellular Carcinoma. Cancer Research, 2022, 82, 1470-1481.	0.4	0
8	Impact of Extended Use of Ablation Techniques in Cirrhotic Patients with Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Cancers, 2022, 14, 2634.	1.7	0
9	Outcome of liver cancer patients with SARSâ€CoVâ€2 infection: An International, Multicentre, Cohort Study. Liver International, 2022, 42, 1891-1901.	1.9	11
10	Benign liver tumours: understanding molecular physiology to adapt clinical management. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 703-716.	8.2	11
11	Biomarkers for Hepatobiliary Cancers. Hepatology, 2021, 73, 115-127.	3.6	104
12	Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target. Journal of Hepatology, 2021, 74, 1155-1166.	1.8	54
13	Genomics of Viral Hepatitis-Associated Liver Tumors. Journal of Clinical Medicine, 2021, 10, 1827.	1.0	7
14	Percutaneous ablation for locally advanced hepatocellular carcinoma with tumor portal invasion. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101731.	0.7	2
15	NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF BENIGN LIVER TUMOURS. Clinics and Research in Hepatology and Gastroenterology, 2021, 46, 101765.	0.7	3
16	Transient elastography predicts survival after radiofrequency ablation of hepatocellular carcinoma developing on cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 142-150.	1.4	5
17	Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma. Hepatology, 2020, 71, 164-182.	3.6	129
18	RSPO2 abnormal transcripts result from read-through in liver tumours with high ÃŸ-catenin activation and CTNNB1 mutations. Gut, 2020, 69, 1152-1153.	6.1	3

#	Article	IF	Citations
19	Acute pericarditis: A rare complication of gastric variceal obturation with cyanoacrylate glue. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, e25-e28.	0.7	3
20	Adeno-associated virus in the liver: natural history and consequences in tumour development. Gut, 2020, 69, 737-747.	6.1	78
21	TIPS for management of portal-hypertension-related complications in patients with cirrhosis. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 249-263.	0.7	22
22	Recurrent chromosomal rearrangements of ROS1, FRK and IL6 activating JAK/STAT pathway in inflammatory hepatocellular adenomas. Gut, 2020, 69, 1667-1676.	6.1	17
23	BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA. Journal of Hepatology, 2020, 72, 924-936.	1.8	44
24	International and multicenter realâ€world study of sorafenibâ€treated patients with hepatocellular carcinoma under dialysis. Liver International, 2020, 40, 1467-1476.	1.9	15
25	The landscape of gene mutations in cirrhosis and hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 990-1002.	1.8	101
26	Optimizing curative management of hepatocellular carcinoma. Liver International, 2020, 40, 109-115.	1.9	19
27	Advances in molecular classification and precision oncology in hepatocellular carcinoma. Journal of Hepatology, 2020, 72, 215-229.	1.8	311
28	Milestones in the pathogenesis and management of primary liver cancer. Journal of Hepatology, 2020, 72, 209-214.	1.8	39
29	Characterizing the mechanism behind the progression of NAFLD to hepatocellular carcinoma. Hepatic Oncology, 2020, 7, HEP36.	4.2	12
30	Multibipolar Radiofrequency Ablation for the Treatment of Mass-Forming and Infiltrative Hepatocellular Carcinomas > 5 cm: Long-Term Results. Liver Cancer, 2019, 8, 172-185.	4.2	22
31	Virologic control and severity of liver disease determine survival after radiofrequency ablation of hepatocellular carcinoma on cirrhosis. Digestive and Liver Disease, 2019, 51, 86-94.	0.4	14
32	Late onset of nivolumab-induced severe gastroduodenitis and cholangitis in a patient with stage IV melanoma. Immunotherapy, 2019, 11, 1005-1013.	1.0	21
33	Natural history of liver adenomatosis: A long-term observational study. Journal of Hepatology, 2019, 71, 1184-1192.	1.8	32
34	Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response. Gastroenterology, 2019, 157, 760-776.	0.6	141
35	The role of telomeres and telomerase in cirrhosis and liver cancer. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 544-558.	8.2	154
36	A Dive Into the Deep Heterogeneity of Hepatocellular Carcinoma. Gastroenterology, 2019, 157, 1477-1479.	0.6	8

#	Article	IF	Citations
37	Dynamic of systemic immunity and its impact on tumor recurrence after radiofrequency ablation of hepatocellular carcinoma. OncoImmunology, 2019, 8, 1615818.	2.1	34
38	A 17â€Betaâ€Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease. Hepatology, 2019, 70, 231-240.	3.6	75
39	Can We Move on From the Discussion of Direct Antiviral Agents and Risk of Hepatocellular Carcinoma Recurrence?. Gastroenterology, 2019, 156, 1558-1560.	0.6	4
40	Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy. Gastroenterology, 2019, 156, 492-509.	0.6	145
41	PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases. International Journal of Cancer, 2019, 144, 533-544.	2.3	72
42	Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma. Journal of Hepatology, 2018, 69, 336-344.	1.8	47
43	The role of molecular enrichment on future therapies in hepatocellular carcinoma. Journal of Hepatology, 2018, 69, 237-247.	1.8	95
44	Macrotrabecularâ€massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance. Hepatology, 2018, 68, 103-112.	3.6	159
45	Reply to: â€œResponse to: Positron emission tomography/computed tomography with 18 F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinomaâ€. Journal of Hepatology, 2018, 69, 555-556.	1.8	2
46	Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas. Hepatology, 2018, 68, 964-976.	3.6	43
47	Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations. Journal of Hepatology, 2018, 68, 783-797.	1.8	271
48	Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress. Nature Communications, 2018, 9, 5235.	5.8	118
49	Systemic AA Amyloidosis Caused by Inflammatory Hepatocellular Adenoma. New England Journal of Medicine, 2018, 379, 1178-1180.	13.9	15
50	Molecular classification of hepatocellular adenomas: impact on clinical practice. Hepatic Oncology, 2018, 5, HEP04.	4.2	34
51	Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity In Vitro. Clinical Cancer Research, 2017, 23, 4364-4375.	3.2	57
52	Cancer Gene Discovery in Hepatocellular Carcinoma: TheÂCRISPR/CAS9 Accelerator. Gastroenterology, 2017, 152, 941-943.	0.6	3
53	Autoimmuneâ€like chronic hepatitis induced by olmesartan. Hepatology, 2017, 66, 2086-2088.	3.6	8
54	Safety and Efficacy of Irreversible Electroporation for the Treatment of Hepatocellular Carcinoma Not Amenable to Thermal Ablation Techniques: A Retrospective Single-Center Case Series. Radiology, 2017, 284, 877-886.	3.6	120

#	Article	IF	Citations
55	Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. Journal of Hepatology, 2017, 67, 727-738.	1.8	525
56	Germline and somatic DICER1 mutations in familial and sporadic liver tumors. Journal of Hepatology, 2017, 66, 734-742.	1.8	31
57	Molecular Classification of Hepatocellular Adenoma AssociatesÂWith Risk Factors, Bleeding, and Malignant Transformation. Gastroenterology, 2017, 152, 880-894.e6.	0.6	290
58	Molecular classification of hepatocellular adenoma in clinical practice. Journal of Hepatology, 2017, 67, 1074-1083.	1.8	119
59	Molecular targets for HCC and future treatments. Journal of Hepatology, 2017, 66, 234-235.	1.8	7
60	Transarterial chemoembolization for early stage hepatocellular carcinoma decrease local tumor control and overall survival compared to radiofrequency ablation. Oncotarget, 2017, 8, 32190-32200.	0.8	15
61	Genotypeâ€phenotype correlation of CTNNB1 mutations reveals different ÃŸâ€catenin activity associated with liver tumor progression. Hepatology, 2016, 64, 2047-2061.	3.6	222
62	Type 2 diabetesâ€“associated hepatocellular carcinoma: A molecular profile. Clinical Liver Disease, 2016, 8, 53-58.	1.0	11
63	Hepatocellular Carcinoma within Milan Criteria: No-Touch Multibipolar Radiofrequency Ablation for Treatmentâ€”Long-term Results. Radiology, 2016, 280, 611-621.	3.6	100
64	Adeno-associated virus type 2 as an oncogenic virus in human hepatocellular carcinoma. Molecular and Cellular Oncology, 2016, 3, e1095271.	0.3	12
65	Stemness of liver cancer: From hepatitis B virus to Wnt activation. Journal of Hepatology, 2016, 65, 873-875.	1.8	6
66	Hepatocellular Carcinoma: the Impact of NAFLD. Current Hepatology Reports, 2016, 15, 190-198.	0.4	2
67	Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution. Journal of Hepatology, 2016, 65, 663-665.	1.8	103
68	The transcriptomic G1â€“G6 signature of hepatocellular carcinoma in an Asian population. Medicine (United States), 2016, 95, e5263.	0.4	6
69	The CRP level and STATE score predict survival in cirrhotic patients with hepatocellular carcinoma treated by transarterial embolization. Digestive and Liver Disease, 2016, 48, 1088-1092.	0.4	14
70	Genetic profiling of hepatocellular carcinoma using next-generation sequencing. Journal of Hepatology, 2016, 65, 1031-1042.	1.8	219
71	Percutaneous Treatment of Localized Infiltrative Hepatocellular Carcinoma Developing on Cirrhosis. Annals of Surgical Oncology, 2016, 23, 1906-1915.	0.7	8
72	Inflammatory hepatocellular adenomas developed in the setting of chronic liver disease and cirrhosis. Modern Pathology, 2016, 29, 43-50.	2.9	45

#	Article	IF	Citations
73	TERT promoter mutations in primary liver tumors. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 9-14.	0.7	78
74	Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology, 2015, 149, 1226-1239.e4.	0.6	980
75	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nature Genetics, 2015, 47, 505-511.	9.4	1,372
76	Intratumor Molecular and Phenotypic Diversity in Hepatocellular Carcinoma. Clinical Cancer Research, 2015, 21, 1786-1788.	3.2	73
77	Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nature Genetics, 2015, 47, 1187-1193.	9.4	387
78	Visceral fat area predicts survival in patients with advanced hepatocellular carcinoma treated with tyrosine kinase inhibitors. Digestive and Liver Disease, 2015, 47, 869-876.	0.4	46
79	Reports from the International Liver Cancer Association (ILCA) congress 2014. Journal of Hepatology, 2015, 62, 477-482.	1.8	7
80	Integration of tumour and viral genomic characterisations in HBV-related hepatocellular carcinomas. Gut, 2015, 64, 820-829.	6.1	127
81	Molecular Determinants of Prognosis in Hepatocellular Carcinoma. Journal of Clinical and Translational Hepatology, 2014, 2, 31-6.	0.7	3
82	Molecular Profiling of Liver Tumors: Classification and Clinical Translation for Decision Making. Seminars in Liver Disease, 2014, 34, 363-375.	1.8	47
83	Genomic Profiling of Hepatocellular Adenomas Reveals Recurrent FRK-Activating Mutations and the Mechanisms of Malignant Transformation. Cancer Cell, 2014, 25, 428-441.	7.7	240
84	Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology, 2014, 60, 1983-1992.	3.6	268
85	Pathogenesis of hepatocellular carcinoma according to aetiology. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 937-947.	1.0	59
86	Genetics of hepatocellular carcinoma: The next generation. Journal of Hepatology, 2014, 60, 224-226.	1.8	59
87	Next generation sequencing, inter-tumor heterogeneity and prognosis of hepatitis B related hepatocellular carcinoma. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2014, 26, 730-1.	0.7	3
88	High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nature Communications, 2013, 4, 2218.	5.8	513
89	Predisposition to hepatocellular carcinoma: Clues in sex chromosomes. Clinics and Research in Hepatology and Gastroenterology, 2013, 37, 547-548.	0.7	0
90	Hepatocellular Benign Tumorsâ€"From Molecular Classification to Personalized Clinical Care. Gastroenterology, 2013, 144, 888-902.	0.6	251

#	Article	IF	Citations
91	Primary Liver Carcinomas Can Originate From Different Cell Types: A New Level of Complexity in Hepatocarcinogenesis. Gastroenterology, 2013, 145, 53-55.	0.6	10
92	A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection. Gastroenterology, 2013, 145, 176-187.	0.6	302
93	Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma. OncoImmunology, 2013, 2, e27090.	2.1	39
94	Serum Proteoglycans as Prognostic Biomarkers of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1343-1352.	1.1	65
95	Molecular Classification of Hepatocellular Adenomas. International Journal of Hepatology, 2013, 2013, 1-7.	0.4	24
96	GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. Journal of Hepatology, 2012, 56, 184-191.	1.8	354
97	Genetics of Hepatobiliary Carcinogenesis. Seminars in Liver Disease, 2011, 31, 173-187.	1.8	138
98	Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. Journal of Experimental Medicine, 2011, 208, 1359-1366.	4.2	218
99	Percutaneous treatments of hepatocellular carcinoma: Improving efficacy, applicability and extending ablation criteria. Liver Cancer International, 0, , .	0.2	0